Drug Enhancement Company of America

Durect is a biopharmaceutical company pioneering the field of epigenetic regulator therapies while maintaining a portfolio of proprietary drug delivery technologies. The company's lead program, larsucitostat (DUR-928), is an endogenous sulfated oxysterol in late-stage development for alcohol-associated hepatitis (AH), a life-threatening condition with no FDA-approved treatments. Durect's commercial portfolio includes POSIMIR, a sustained-release local analgesic for post-operative pain, and the ALZET product line of osmotic pumps for animal research. The company utilizes its SABER and ORADUR platforms to develop long-acting injectable and oral formulations of various therapeutics. Durect is headquartered in Cupertino, California, and is listed on the Nasdaq Capital Market.